<DOC>
	<DOCNO>NCT02282293</DOCNO>
	<brief_summary>This double-blinded , randomize control trial 200 HIV-infected pregnant woman live Tororo , Uganda , area high malaria transmission . HIV-infected pregnant woman 12 28 week gestation randomize receive enhance malaria chemoprevention monthly dihydroartemisinin-piperaquine ( DP ) versus monthly DP placebo . Their HIV-exposed child receive prevention regimen 2 24 month age mother randomize . All woman receive daily trimethoprim-sulfamethoxazole ( TS ) throughout study per Uganda Ministry Health guideline . Children also receive daily TS 6 week 24 month age . TS consider study drug infant child begin 6 week cessation breastfeed upon exclusion HIV infection . Women child follow 36 month delivery . In subset study population , investigator conduct intensive pharmacokinetic study evaluate pharmacokinetic exposure DP EFV . The investigator also measure HIV-related outcome among woman enrol study . The investigator test hypothesis HIV-infected mother HIV-exposed infant , enhance versus standard malaria chemoprevention HIV-infected pregnant woman child reduce incidence malaria among child 0 24 month age improve development naturally acquire antimalarial immunity .</brief_summary>
	<brief_title>Reducing Burden Malaria HIV-Infected Pregnant Women Their HIV-Exposed Children ( PROMOTE-BC2 )</brief_title>
	<detailed_description>Pregnant woman schedule see study clinic every 4 week pregnancy . Women see 1 week , 6 week , 3 month postpartum every 3 month thereafter . In addition , pregnant woman instruct come study clinic medical care avoid use outside medication . Women provide routine HIV care clinic accord Uganda MOH guideline . All woman ARVs TS dispense study clinic . Counseling breastfeed infant feeding provide per Uganda MOH guideline . HIV care breastfeed infant feeding recommendation may change reflect recent standard care per MOH guideline . Children schedule see clinic every 4 week parent /guardians child instruct bring child study clinic medical care avoid use outside medication . The study clinic remain open 7 day week 8 a.m. 5 p.m. Each time study participant see clinic standardized history physical exam perform . Patients febrile ( tympanic temperature &gt; 3 8.0ËšC ) report history fever past 24 hour blood obtain finger prick thick blood smear . If thick blood smear positive , patient diagnose malaria . If thick blood smear negative , patient manage study physician non-malarial febrile illness . If patient afebrile report recent fever , thick blood smear obtain , except follow routine test schedule . Routine assessment do clinic every 4 week pregnant woman child . Pregnant woman child receive standard care designate Uganda MOH guideline . Children care HIV-exposed child accord MOH guideline , exception TS continue 2 year life . Routine care child use Integrated Management Childhood Illness ( IMCI ) guideline . During routine assessment subject ask visit outside health facility use medication outside study protocol . Standardized assessment adherence also do study drug administer home Insecticide Treated Net use . A routine history physical exam perform use standardized clinical assessment form . Blood collect finger prick thick smear , collection plasma PK study , filter paper sample . Phlebotomy routine laboratory test ( CBC ALT ) monitor potential adverse event study medication immunology study perform every 8 week pregnant woman every 16 week child . Non malaria screen also include stool ova parasite examination , circulate filarial antigen ( ICT card Wucheria ) , blood smear microfilaremia ( include Mansonella perstans ) use Knott 's technique . For pregnant woman child 2-24 month age , study drug administer time routine visit .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dihydroartemisinin</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<criteria>1 . Intrauterine pregnancy confirm ultrasound 2 . Estimated gestational age 1228 week 3 . Confirmed HIVinfected Uganda country standard rapid HIV test 4 . 16 year age old 5 . Residency within 30 km study clinic 6 . Provision inform consent 7 . Agreement come study clinic febrile episode illness avoid medication give outside study protocol 8 . Plan deliver hospital 1 . History serious adverse event TS DP 2 . Refusal take cART pregnancy part routine HIV care 3 . Active medical problem require inpatient evaluation time screen 4 . Intention move 30 km study clinic 5 . Active WHO stage 4 condition stable treatment 6 . Signs symptoms early active labor 7 . Currently ritonavir 8 . Currently take drug associate know risk Torsades de point 9 . Currently take CYP3A inhibitor medication potentially inhibit metabolism piperaquine 10 . History cardiac problem faint</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Chemoprevention</keyword>
	<keyword>Malaria</keyword>
	<keyword>Uganda</keyword>
	<keyword>Dihydroartemisinin-piperaquine</keyword>
	<keyword>Trimethoprim-sulfamethoxazole</keyword>
	<keyword>Human Immunodeficiency Virus</keyword>
</DOC>